The biotech has launched a strategic review to consider options, including a possible sale, following shareholder pressure.

In pulmonary hypertension, a combination of metabolic and mechanical dysfunction leads to irreversible vascular damage.

Considerable variability exists in the clinical presentations of pulmonary arterial hypertension (PAH). Greater understanding of the comorbidities observed in Chinese patients with PAH is urgently ...

Treatments approved for PAH may reduce by half the risk of serious complications or death in patients with repaired ...

A recent publication in the International Journal of Cardiology, Pulmonary artery denervation in pulmonary hypertension: A comprehensive meta-analysis, has shed light on the potential of pulmonary ...

Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and ...

The findings from this single-center retrospective study compare outcomes between 2 groups of patients living with connective tissue disease–associated pulmonary arterial hypertension (CTD-PAH) ...

In April 2025, Actelion announced a study is to demonstrate superiority of macitentan 75 milligrams (mg) in prolonging the ...

Pulmonary arterial hypertension (PAH) is a rare form of pulmonary hypertension. It occurs because progressive vascular ...

The new drug sotatercept stops the remodelling of the pulmonary vessels and even helps patients with advanced pulmonary arterial hypertension (PAH) who have not yet been treated.

Liquidia's collaboration with Sandoz and development of new products like L606 show promise. Learn why LQDA stock is a Hold.

A new study from Thailand shows that a rapid peak in skin thickness progression in systemic sclerosis patients may predict ...